邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

共识与争议:绝经激素治疗与乳腺癌发病风险

徐颖,  林燕,  王常珺,  孙强

downloadPDF
文章导航 > 协和医学杂志  > 2018 >  9(4): 332-335
徐颖, 林燕, 王常珺, 孙强. 共识与争议:绝经激素治疗与乳腺癌发病风险[J]. 协和医学杂志, 2018, 9(4): 332-335. doi: 10.3969/j.issn.1674-9081.2018.04.008
引用本文: 徐颖, 林燕, 王常珺, 孙强. 共识与争议:绝经激素治疗与乳腺癌发病风险[J]. 协和医学杂志, 2018, 9(4): 332-335. doi: 10.3969/j.issn.1674-9081.2018.04.008
shu
Ying XU, Yan LIN, Chang-jun WANG, Qiang SUN. Consensus and Controversy: Menopausal Hormone Therapy and the Risk of Breast Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(4): 332-335. doi: 10.3969/j.issn.1674-9081.2018.04.008
Citation: Ying XU, Yan LIN, Chang-jun WANG, Qiang SUN. Consensus and Controversy: Menopausal Hormone Therapy and the Risk of Breast Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(4): 332-335. doi: 10.3969/j.issn.1674-9081.2018.04.008
shu

共识与争议:绝经激素治疗与乳腺癌发病风险

doi: 10.3969/j.issn.1674-9081.2018.04.008

  • 中国医学科学院 北京协和医学院 北京协和医院乳腺外科, 北京 100730

详细信息
    通讯作者:

    孙强 电话:010-69152700, E-mail:sunqiangpumc@sina.com

  • 中图分类号: R459.1;R737.9

Consensus and Controversy: Menopausal Hormone Therapy and the Risk of Breast Carcinoma

  • Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences ＆ Peking Union Medical College, Beijing 100730, China

More Information

    摘要
  • 摘要: 绝经激素治疗(menopausal hormone therapy,MHT)是以雌激素补充为核心的治疗,在有子宫的女性治疗中往往需联合雌激素和孕激素。妇科内分泌和乳腺外科专家就围绝经期MHT是否增加乳腺癌风险展开讨论并达成共识:MHT可增加乳腺癌风险,应用时需全面评估风险与收益;MHT存在用药窗口期、用药指征、禁忌证,应用前需告知患者相关风险并取得知情同意。对天然孕激素、替勃龙及单雌激素治疗是否增加乳腺癌发生风险等问题仍存在争议。
    Abstract: Menopausal hormone therapy (MHT) is the medical treatment that mitigates menopausal symptoms with administration of supplementary sexual hormones. Estrogen and progesterone are often involved in MHT. Experts from the Department of Gynecologic Endocrine and the Department of Breast Surgery have paid special attention to the risk of breast carcinoma related to MHT and reached consensuses on the following issues:MHT increases the risk of breast carcinoma; decision should be made after a careful and comprehensive assessment of the risk of breast carcinoma and the potential benefit of MHT. Since the administration of MHT has a window period, a thorough discussion with patients is essential to fully inform the indication and contraindication of MHT, and an informed consent should be obtained. There are still controversies over the risk of breast carcinoma with natural progesterone, tibolone, and single estrogen.
    • HTML全文
    • 参考文献(19)
  • [1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J].CA Cancer J Clin, 2015,65:87-108. doi:  10.3322/caac.21262
    [2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66:115-132. doi:  10.3322/caac.21338
    [3] Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China[J]. Lancet Oncol,2014,15: e279-e289. doi:  10.1016/S1470-2045(13)70567-9
    [4] Rossouw JE, Anderson GL, Prentice RL, et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial[J].JAMA,2002,288: 321-333. doi:  10.1001/jama.288.3.321
    [5] Chlebowski RT, Rohan TE, Manson JE, et al.Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials[J].JAMA Oncol, 2015, 1: 296-305. doi:  10.1001/jamaoncol.2015.0494
    [6] JoAnn E,Manson PH, Rowan T, et al.The Women's Health Initiative Hormone Therapy Trials: Update and Overview of Health Outcomes During the intervention and Post-stopping Phases[J]. JAMA, 2013,301:1353-1368. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1177/0148607102026001011
    [7] Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study[J].Lancet, 2003, 362: 419-427. doi:  10.1016/S0140-6736(03)14065-2
    [8] Reeves GK, Beral V, Green J, et al. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis[J].Lancet Oncology,2006, 7: 910-918. doi:  10.1016/S1470-2045(06)70911-1
    [9] Stahlberg C, Pedersen AT, Andersen ZJ, et al.Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy[J].BJC,2004,91:644-650. doi:  10.1038/sj.bjc.6601996
    [10] Saxena T, Lee E, Henderson KD, et al. Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study[J]. Cancer Epidemiol Biomarkers Prev, 2010,19: 2366-2378. doi:  10.1158/1055-9965.EPI-10-0162
    [11] Simin J, Tamimi R, Lagergren J, et al. Menopausal hormone therapy and cancer risk: An overestimated risk?[J]. Eur J Cancer,2017,84: 60-68. doi:  10.1016/j.ejca.2017.07.012
    [12] Wang K, Li F, Chen L,et al. Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies[J].Oncotarget, 2017,8:81109-81124. doi:  10.18632/oncotarget.20154
    [13] Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort[J]. Int J Cancer, 2005,114:448-454. doi:  10.1002/ijc.20710
    [14] Lyytinen H, Pukkala E, Ylikorkala O. Breast Cancer Risk in Postmenopausal Women Using Estradiol-Progestogen Therapy[J].Obstet Gynecol, 2009,113:65-73. doi:  10.1097/AOG.0b013e31818e8cd6
    [15] Baber RJ, Panay N, Fenton A, et al.2016 IMS Recommendations on women's midlife health and menopause hormone therapy[J].Climacteric,2016,19:106-150. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.3109/13697137.2015.1129166
    [16] LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial[J]. JAMA, 2011, 305:1305-1314. doi:  10.1001/jama.2011.382
    [17] Fournier A, Mesrine S, Dossus L, et al. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort[J]. Breast Cancer Res Treat, 2014,145:535-543. doi:  10.1007/s10549-014-2934-6
    [18] Cummings SR, Ettinger B, Delmas PD, et al.The effects of tibolone in older postmenopausal women[J].NEJM,2008, 359: 697-708. doi:  10.1056/NEJMoa0800743
    [19] Maas P, Barrdahl M, Joshi AD, et al. Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States[J]. JAMA Oncol,2016,2:1295-1302. doi:  10.1001/jamaoncol.2016.1025
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  316
  • HTML全文浏览量:  43
  • PDF下载量:  244
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-03-28
  • 刊出日期:  2018-07-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！